Abstract 5494
Background
Oncogenic fibroblast growth factor receptor (FGFR) gene fusions have been described in diverse tumor histology. FGFR inhibitors including erdafitinib have demonstrated promising results in patients whose tumors harbor FGFR gene fusions or mutations. We hereby assessed the frequency of FGFR rearrangements in the Chinese non-small cell lung cancer (NSCLC) population.
Methods
A total of 10,966 NSCLC patients whose tumor specimen and/or circulating cell-free DNA (cfDNA) submitted for genomic profiling by hybridization capture-based targeted next-generation sequencing (NGS) of exons and introns of cancer related genes were retrospectively reviewed. Patients’ clinical characteristics and treatment history were retrieved from the database for further evaluation.
Results
FGFR fusions retaining the intact kinase domain were identified in 0.11% (12/10966) of NSCLC cases examined, including 9 fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil containing protein 3 gene (TACC3) fusion-positive cases that was mostly reported in solid tumors, one fibroblast growth factor receptor 2 (FGFR2)-internexin neuronal intermediate filament protein α gene (INA) fusion that was previously reported in gliomas, one novel fibroblast growth factor receptor 4 (FGFR4)-Rap guanine nucleotide exchange factor like 1 gene (RAPGEFL1) fusion case, and one novel fibroblast growth factor receptor 1 (FGFR1) gene fusion involving the 5’UTR of Solute Carrier Family 20 Member 2 gene (SLC20A2) which may possibly drive the overexpression of FGFR1. Concomitant EGFR mutations or EGFR amplification were observed in 6 patients, four of which were previously treated with EGFR tyrosine kinase inhibitors (TKIs), but disease progressed prior to NGS tests. FGFR fusions may arise as resistance mechanism to EGFR TKI therapies in patients who carried founder EGFR alterations. No other known concurrent driver mutations were detected in the remaining 6 cases.
Conclusions
We hereby report a frequency of FGFR fusions of 0.11% in a large Chinses NSCLC population involving known and novel FGFR gene fusion partners including TACC3, INA, RAPGEFL1, and SLC20A2. Oncogenic FGFR fusions may arise as mechanisms of acquired resistance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Geneseeq Technology Inc.
Funding
Has not received any funding.
Disclosure
Q. Ou: Full / Part-time employment, NA: Geneseeq Technology Inc. X. Wu: Leadership role, NA: Geneseeq Technology Inc. X. Wang: Full / Part-time employment, NA: Nanjing Geneseeq Technology Inc. Y.W. Shao: Leadership role, NA: Geneseeq Technology Inc. All other authors have declared no conflicts of interest.
Resources from the same session
5444 - Analysis of the tumor microenvironment and tumor genotype through different stages of lung adenocarcinoma
Presenter: Peter Zink
Session: Poster Display session 1
Resources:
Abstract
3124 - Does Progress achieved in the Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) reach the Elderly Population?
Presenter: Jorune Suipyte
Session: Poster Display session 1
Resources:
Abstract
5142 - Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)
Presenter: Yoshihito Ohhara
Session: Poster Display session 1
Resources:
Abstract
1580 - A novel risk classification system based on nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC
Presenter: Pengfei Cui
Session: Poster Display session 1
Resources:
Abstract
4442 - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Xinran Ma
Session: Poster Display session 1
Resources:
Abstract
5405 - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Presenter: Parneet Kaur Cheema
Session: Poster Display session 1
Resources:
Abstract
1893 - SMARCA4 Deficient Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study
Presenter: Stephen Graziano
Session: Poster Display session 1
Resources:
Abstract
5582 - Exploring Resistance to Nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
Presenter: Sara Pilotto
Session: Poster Display session 1
Resources:
Abstract
1408 - DNA damage repair deficiency is associated with early resistance to crizotinib: whole-genome analysis in non-small cell lung cancer patients with ALK-fusion
Presenter: Dongyun He
Session: Poster Display session 1
Resources:
Abstract
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract